NCT03165071View on ClinicalTrials.gov

A Study to Evaluate ACT-132577 in Healthy Subjects and in People With Severe Kidney Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

June 3, 2017

Primary Completion Date

October 27, 2017

Study Completion Date

October 27, 2017

Conditions
Severe Renal ImpairmentHealthy Subjects
Interventions
DRUG

ACT-132577

Capsule

Trial Locations (1)

32300

CEPHA, Pilsen

Sponsors
All Listed Sponsors
lead

Idorsia Pharmaceuticals Ltd.

INDUSTRY

NCT03165071 - A Study to Evaluate ACT-132577 in Healthy Subjects and in People With Severe Kidney Disease | Biotech Hunter | Biotech Hunter